ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1301

The Relationship Between Socioeconomic Factors and Persistent Active Rheumatoid Arthritis: Results from (NEIAA) a Large UK Cohort of Early Inflammatory Arthritis

Maryam Adas1, Sam Norton1, Andrew Cope1, Maya Buch2, James Galloway1 and Elena Nikiphorou1, 1King's College London, London, United Kingdom, 2University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom

Meeting: ACR Convergence 2023

Keywords: mental health, prognostic factors, registry, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1264–1307) RA – Diagnosis, Manifestations, and Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Psychosocial factors may interplay with biological factors to drive a refractory disease state in patients with inflammatory arthritis1. We aim to explore which socioeconomic, and disease related factors associated with persistent active rheumatoid arthritis (PactiveRA) in the first year, despite use of conventional synthetic DMARDs.

Methods: NEIAA is an observational cohort of adult patients with early RA patients in England and Wales. Data from May 2018 until Oct 2022 were acquired. All patients fulfilled the ACR/EULAR 2010 criteria for RA. Patients were defined as having PactiveRA based on three consecutive Disease Activity Scores (DAS28) of >3.2 at baseline, three and 12 months of follow up. Controlled RA (contRA) was defined as patients started with high DAS28 >3.2 at baseline then entered remission (DAS28 ≤ 3.2 at the three and 12 month time-points). PactiveRA status was used as the primary outcome variable. Univariable, followed by multivariable analyses stepwise forward logistic regression to explore associations with PactiveRA. Age and gender were included in the models as a priori, with socioeconomic variables handled as the main independent variables (social deprivation, smoking-status and comorbidities) of interest, followed by disease related factors.

Results: A total of 15,626 patients had a diagnosis of RA in NEIAA. Of which, 682 patients with pactiveRA and 1,026 patients with contRA were analysed. Compared to contRA, patients with PactiveRA were younger (aged 58, interquartile range (IQR): 49, 67) vs (62, IQR: 52,72), included more females 471 (69%) vs 607 (59%), were current or ex-smokers, and more likely to have depression, lung and gastrointestinal disease.

Also, patients with PactiveRA had worse scores in Patient Reported Outcomes at baseline and Patient Health Questionnaire Anxiety and Depression Screener. Logistic regression results are summarised in the table. Age, gender, living in a socially deprived area and being an ex or current smoker, were associated with PactiveRA in models controlling for markers of disease severity (seropositivity). Baseline corticosteroid use was also associated with PactiveRA (p< 0.05 for all) and having a concomitant diagnosis of depression, odds ratio (OR) 2.30 (95%CI: 1.67,3.17), lung disease OR 1.46 (95%CI: 1.14,1.86) and gastric ulcer OR 1.71 (95%CI: 1.17,2.50) were significantly related to PactiveRA.

Conclusion: Sociodemographic factors and living in socially deprived areas were all associated with PactiveRA, independent of clinical and disease characteristics. Identifying ‘adverse’ socioeconomic factors that could drive persistent active disease early in the disease process, can help better guide interventions that would be suitable for individual patients and their respective needs.

Supporting image 1


Disclosures: M. Adas: None; S. Norton: Janssen, 6, Pfizer, 6; A. Cope: Bristol-Myers Squibb(BMS), 2, 5, 6; M. Buch: AbbVie, 2, 6, 12, All paid to host institution, Boehringer Ingelheim, 2, 6, 12, Paid to host institution, Galapagos, 2, 6, 12, Paid to host institution, Gilead, 2, 5, 6, 12, Paid to host institution, Lilly, 2, 6, 12, All paid to host institution, National Insitute for Health and Care Research (NIHR), 3, 12, Maya H Buch is a National Institute for Health and Care Research (NIHR) Senior Investigator. The views expressed are those of the authors and not nece, Pfizer, 2, 12, Paid to host institution; J. Galloway: AbbVie, 2, 5, 6, AstraZeneca, 5, Biogen, 6, Eli Lilly, 2, 5, 6, Galapagos, 2, 5, 6, Janssen, 2, 5, 6, Pfizer, 2, 5, 6, UCB, 2, 5, 6; E. Nikiphorou: AbbVie/Abbott, 6, Celltrion, 6, Eli Lilly, 6, fresenius, 6, Galapagos, 6, Gilead, 1, 6, Pfizer, 6, Sanofi, 6.

To cite this abstract in AMA style:

Adas M, Norton S, Cope A, Buch M, Galloway J, Nikiphorou E. The Relationship Between Socioeconomic Factors and Persistent Active Rheumatoid Arthritis: Results from (NEIAA) a Large UK Cohort of Early Inflammatory Arthritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/the-relationship-between-socioeconomic-factors-and-persistent-active-rheumatoid-arthritis-results-from-neiaa-a-large-uk-cohort-of-early-inflammatory-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-relationship-between-socioeconomic-factors-and-persistent-active-rheumatoid-arthritis-results-from-neiaa-a-large-uk-cohort-of-early-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology